



Available online through

www.jbsoweb.com

ISSN 2321 - 6328

Research Article

ROLE OF TOPICAL APPLICATION OF SHRINGVERADI EYE DROPS IN NETRABHISYANDA WITH SPECIAL REFERENCE TO ALLERGIC CONJUNCTIVITIS

Kanaujia Sakshi ^{1*}, Kumar Manoj ²

¹PG Department of Shalakyta Tantra, Junior Resident, Banaras Hindu University, Varanasi, India

²Associate Professor, PG Department of Shalakyta Tantra Banaras Hindu University, Varanasi, India

*Corresponding Author Email: sakshi.kanaujia@gmail.com

Article Received on: 21/06/15 Accepted on: 13/08/15

DOI: 10.7897/2321-6328.03437

ABSTRACT

Ocular allergy manifests as a number of distinct disease entities, ranging from allergic conjunctivitis, a relatively mild condition, to keratoconjunctivitis, which may be sight-threatening condition affecting the cornea. Underlying immune mechanism behind this has not yet been fully understood, but it is known that IgE related mast cell and eosinophil mediated inflammation leads to the release of mast cell mediators and toxic eosinophil granule protein and enzymes. Patients suffering from ocular allergy might experience such symptoms such as redness, itching, burning, swelling or dryness in eyes in differing degrees of severity and duration. Based on clinical features Allergic conjunctivitis can be correlated with Abhisyanda of predominantly a Kaphaja etiology. The features like itching, edema of conjunctiva and lid, heaviness of eyelid indicate Kaphaja etiology of allergic conjunctivitis. Features like burning sensation indicate vitiation of Pitta. Dryness of eye indicates vitiation of Vata. Redness suggests vitiation of Rakta. Hence, features of allergic conjunctivitis are mainly linked with Kaphaja activity with subsidiary action of other doshas. To search a safe, potent and cost-effective Ayurvedic treatment for Netrabhisyanda a randomized control clinical trial was conducted on 67 patients. Patients were divided in three groups 25 in Group I (Control Group i.e. Ketotifen 0.025%), 27 in group II (trial Group i.e. Shringveradi Drops) and 15 in Group II I (Placebo i.e. Normal saline) treated topically four times per day for 14days. The effect of Ayurvedic management was found to be equivalent to the standard therapy and more effective than placebo, although the trial drug showed more effect in blepharitis and follicles in lower palpebral conjunctiva. Study shows that Shringveradi eye drops can be used as potent, safe and cost-effective treatment to ameliorate the symptoms of allergic conjunctivitis.

Keywords: Allergic conjunctivitis, Kaphaja Abhisyanda, Shringveradi eye drops

INTRODUCTION

Ocular allergy manifests as a number of distinct disease entities, ranging from allergic conjunctivitis, a relatively mild condition to Keratoconjunctivitis, a sight threatening condition affecting the cornea¹. It is a group of disease which includes Seasonal allergic conjunctivitis (SAC), Perennial allergic conjunctivitis (PAC), Vernal allergic conjunctivitis (VKC), Atopic Allergic conjunctivitis (AKC) and Giant papillary allergic conjunctivitis (GPC). All these forms of allergic conjunctivitis, for many years, were considered as the results of classical type 1 IgE-mediated hypersensitivity reaction of conjunctival tissue. More recent studies, however suggest that whole of ocular surface including lids, conjunctiva, cornea and tear film is involved in pathological process.

The cellular components and pro-inflammatory mediators are responsible for development of inflammation in ocular surface tissue. The inflammation clinical manifests in the form of symptoms of itching, watering, photophobia etc., and signs of redness, papillary response, lid swelling etc².

Allergic conjunctivitis is correlated with Netrabhisyanda of kapha predominance with varying degree of involvement of other doshas viz. vata and pitta. There are numbers of formulations described in Ayurveda to control this condition. These formulations are though new no or fewer side effects and well tolerated by patients.

The purpose of this study is to find out the clinical efficacy of ophthalmic drops based on a formulation described in Suhruta Samhita Uttaratantra Chapter 11 Verse 18 for the treatment of Kaphaja Abhisyanda. The constituents herbs i.e. Shringvera (*Ginger officinale*), Mustaka, (*Cyperus rotundus*), Surdaru (*Cedrus deodara*), Jati Mukul (*Jasminum officinale*) and Saindhava *lavana* have shown anti-allergic anti-inflammatory, anti-microbial and wound healing activity in various experimental studies.

Study Design

This is a short-term, randomized placebo (Normal saline) and controlled clinical trial (Ketotifen 0.025% as a control drug) to evaluate the efficacy of "Shringveradi eye drops" on the course of Allergic conjunctivitis.

MATERIAL AND METHODS

Preparation of Drugs

The formulation was prepared in laboratory of Department of Shalakyta Tantra, Faculty of Ayurveda, Institute of Medical Science, BHU and Varanasi.

Procedure

Shringveradi eye drops were prepared by preparing decoction of above ingredient and filtered with help of fine cloth and residue was discarded. Then this filtrate was centrifuged at 2500 rpm for

20 min. The supernatant portion was taken, purified Saindhava lavana (7.2 gm or 0.9% of solution) was added to this and make it an isotonic solution.

After this solution were autoclaved at 120°C temperature for 15 minutes. The autoclaved solution was filled in 10ml pre-autoclaved dispensing bottles under sterile conditions. PH range of this solution was in between 6.8 – 7.4 in different batches of preparation.

Microbial culture was done on the day of preparation, 10 days after preparation and after 60 days of preparation which was negative, indicating that at least for 2 months the preparation remained sterile without necessity to add preservatives.

Experimental study

Shringveradi eye drops were instilled in eyes of rats to see any adverse effects. There were no adverse effects observed after 1, 6 and 24 hours of instillation of first dose.

Sample size

A total 134 eyes of 67 patients were recruited for this study as bilateral nature of disease. Groups and randomization – 67 patient were randomly divided into 3 groups –

- Groups 1 (Control Group) :
50 eyes were kept in this group.
- Group 2 (Trial Group) :
54 eyes were kept in this group
- Group 3 (placebo) :
30 eyes were kept in this group.

Selection of patients

The present clinical study was carried out in Department of Shalakya Tantra and upgraded Department of ophthalmology, Sir Sunder Lal Hospital, Institute of Medical Science, Banaras Hindu University, Varanasi from 1 Aug. 2012 to 1 Dec. 2013. Ethical clearance number: Dean/2011-2012/399 (date: 12-12-2011)

Dose and Dosage

In each group patient received eye drops 4 times / day in dose of 2 drops per instillation for 14 days.

Inclusion criteria

Male and female subjects aged 5 years or older were randomly assigned who were suffering from allergic conjunctivitis which was diagnosed on the basis of their history, bilateral signs and symptoms.

Exclusion criteria

Patients without any concomitant disease of eye which can interfere outcome of therapy were excluded. Patients with ocular surgery within 3 months of study or taking systemic or ocular corticosteroids or mast cell stabilizers within 2 weeks were excluded from study.

Assessment criteria

Assessment was done on already standardized grading scale of symptoms and signs with score of severity 0 to 4³. Other criteria are evaluation of novel scoring system named 5-5-5 exacerbations grading scale for Allergic conjunctivitis disease⁴.

Table 1: Assessment of individual symptom and signs

Score	Description
Itching	
0	Absent
1	An intermittent tickle sensation involving more than just the inner corner of the eye.
2	A mild continuous itch (can be localized) not requiring eye rubbing.
3	A definite itch, the subject would like to able to rub eye
4	An incapacitating itch which would require significant eye rubbing
Tearing	
0	Absent
1	Mild (eyes feel slightly watery)
2	Moderate (occasional need to wipe eyes)
3	Severe (tears rolling down cheeks)
Redness	
0	Absent (vessels normal)
1	Mild (some vessels definitely injected above normal)
2	Moderate (diffusely red eye with individual vessels dilated but still discernible)
3	Severe (intensely red eye with intensive dilatation of conjunctival vessels which are still but not easily visible)
Eyelid swelling	
0	Absent
1	Mild (lids are a little puffy)
2	Moderate (frank swelling of upper and lower lids)
3	Severe (eyelids are swollen)

Table 2: Exacerbation grading scale


Grade of clinical sign	100-point-grade	10-point-grade	1-point-grade
Clinical signs	<ul style="list-style-type: none"> Active giant papillae Gelatinous infiltrates of the limbus Exfoliative epithelial keratopathy Shield Ulcer Papillary proliferation at lower palpebral conjunctiva 	<ul style="list-style-type: none"> Blepharitis Papillary proliferation with velvety appearance Horner-Trantas spots Edema of bulbar conjunctiva Superficial punctate keratopathy 	<ul style="list-style-type: none"> Papillae at upper palpebral conjunctiva Follicular lesion at lower palpebral conjunctiva Hyperemia of palpebral conjunctiva Hyperemia of bulbar conjunctiva Lacrimal effusion
Score	100 points × number of positive signs	10 points × number of positive signs	1 point × number of positive signs
Rang	0-500 point	0-50 point	0-5 point

Statistical Methods

The group was statistically analyzed by applying “chi-square test” (between group comparisons) and “Wilcoxon Singed Rank test” (within group comparison)


Demographic Profile

Data show that all three groups are comparable with each other in terms of age, sex, occupation, socio-economic and marital status of the patient.




CLINICAL PROFILE


Itching : Clinically and statistically, the effect of trial group on itching was better than placebo but not better than control groups (Figure 1).




Watering: Clinically and statistically, the effect of trial drug on watering was slightly less than control group and better than placebo group (Figure 2).




Redness : The effect of trial drug on redness was slightly less than control but no any effect on redness of placebo group(Figure 3).




Lid swelling : The effect of trial drug on lid swelling was not better than control but much better than placebo group (Figure 4).




Papillae at lower palpebral conjunctiva : The effect of trial drug on papillae at lower palpebral conjunctiva was less than control group but much better than placebo group(Figure 5).




Blephritis : The effect of trial gorup on blephritis was much better than control and placebo group (Figure 6)



Edema of bilbar conjunctiva
The effect of trial drug on edema of bulbar conjunctiva was slightly less than control group (Figure 7).




Upper palpebral conjunctiva -The effect of trial drug on papillae at upper palpebral conjunctiva was slight less than control group but better than placebo group (Figure 8).





Follicle at lower palpebral conjunctiva

The effect of trial drug on follicle was slightly better than control group and much better than placebo group (Figure 9).




Hyperemia of palpebral conjunctiva and bulbar conjunctiva : The effect and lacrimation of trial drug on Hyperemia of palpebral(Fig:10) and bulbar conjunctiva (Figure 11). was less than control group, but much better than placebo.





Result on Novel scoring system of 5-5-5 exacerbation grading scale of allergic conjunctivitis. The effect of trial group was better than placebo but not better than control group. Figure 22).



DISCUSSION

Allergic conjunctivitis can be correlated with “Abhisyanada” it has been mentioned in review that various etiological factors of eye disease seasonal changes, atmosphere changes and habitual factors of the patient, immunological status of patient etc. contribute in occurrence of Abhisyanada.⁵

Based on clinical features Allergic conjunctivitis can be correlated with Abhisyanada of predominantly kaphaja etiology.

The features like itching edema of conjunctiva and lid, heaviness of eyelid indicate kaphaja etiology of Allergic conjunctivitis. Features like burning sensation indicate vitiation of pitta. Dryness of eye indicates vitiation of vata. Redness suggests vitiation of rakta. Hence features of Allergic conjunctivitis are mainly linked with kaphaja activity with subsidiary action of other doshas.

Probable mechanism of drug action

The “Shringveradi eye drops” contains four drugs namely Shunti, Mustak, Devdaru Jati-Mukul and Saindhava. Shunti, Mustak and Devdaru have katu guna and katu vipaka which causes kaphanashak, kandunashaka, krimighna which alleviates itching lid and conjunctival swelling.⁶

Tikta rasa is also present in most of content of Shringveradi eye drop. Tikta rasa has vishaghna, krimighana and dahashamak properties alleviates abhisyanada and itching⁷. Lagu guna is shrotas shodhaka which is present in all herbs of trial drug which alleviates kapha⁸.

Properties of Saindhava are lagu, Snigdha and sheeta which cause agnidipana, pachana shrotoshodhaka and kaphavishyandana⁹. By these properties Shringveradi eye drop has capacity to alleviate the disease originating from kapha causes.

According to pathogenesis of Allergic conjunctivitis, Shunti (*Zingiber officinale*) has anti-inflammatory property and analgesic property¹⁰. It has also anti-oxidant properties¹¹.

Some constituent of ginger also inhibit growth of bacteria like staphylococcus¹². Mustak (*Cyperus rotundus*) possess anti-inflammatory and analgesic property¹³. Devdaru (*Cedrus deodara*) also shows anti-inflammatory properties¹⁴.

Jati (*Jasminum officinale*) again shows anti-inflammatory anti-microbial and analgesic activity¹⁵⁻¹⁶⁻¹⁷.

CONCLUSION

“Shringveradi eye drop” has a combination of ingredients which possess different properties which may be acting at various levels to control the disease. The drug may not have strong anti-inflammatory, anti-allergic and anti-microbial activities but the overall effect of all properties acting in combination on disease is significant and comparable with ketotifen (0.025%). It can be concluded that trial drug is though less effective as compared to control drug in providing symptomatic relief and altering the course of disease but it is a good candidate for further studies to be conducted on individual phytochemicals present in the formulation or higher concentration of same combination. It is recommended that this study may be considered as a lead for future studies which can be taken up to carry out standardization of shringveradi eye drop and determine the effect of individual.

REFERENCES

1. Foster CS, Cologne M. Atopic keratoconjunctivitis, ophthalmology 1990; 97:992-1000.
2. Bielory L, Friedlander MH, Allergic conjunctivitis, Immunol Allergy Clin North Am 28 (1) 43-58 doi-10.1016/j.ac.2007.12.PMID.1828545
3. M Kidd, I Steven, C Cooper, R Lanz, Efficacy and safety of Ketotifen eye drops in the treatment of seasonal allergic conjunctivitis, Br. J. Ophthalmol. 2003; 87: 1206-1211.
4. Jun Shoji, Noriko, Inada and Mitsuru Sawa, Evaluation of Novel Scoring System Named 5-5-5 exacerbations grading scale for Allergic Conjunctivitis Disease, Allergology international 2009; 58 : 591-597.
5. Sushruta.Samita.Uttar tantra.1/26-27, Ayurveda Tattva Sandipika Commentary Kaviraj Ambikadutta Shastri, editor, Varanasi Chaukhambha Orientalia, Edition: Reprint 2008. Pg- 11
6. Charak. Samhita Sutra 26/43, Vidhyotini Commentary, Shri Satyanarayanan Shastri, editor, Varanasi Chaukhambha Vishwabharti Academy, Edition: Reprint 2005. Pg- 506
7. Charak.Samhita.Sutra. 26/43, Vidhyotini Commentary , Shri Satyanarayanan Shastri
8. Varanasi Chaukhambha Vishwabharti Academy, , Edition: Reprint 2005. Pg- 507
9. Priyavarta Sharma, Dravya guna Vigyanaya, Varanasi Chaukhambha Bharti Academy , Edition: Reprint 2004.Pg-138
10. Charak.Samhita.Sutra. 26/43, Vidhyotini Commentary, Shri Satyanarayanan Shastri, Varanasi Chaukhambha Vishwabharti Academy, Edition: Reprint 2005, pg- 505

11. Raji Y, Udoh US, Oluwadana OO, Anti-inflammation and analgesic properties of rhizome of extract of *Z. officinale*. Afr. J. Bio Med. Res. 2002; 5: 121-124
12. Ma. J, Jin X, Yang L. Diarylheptanoids form the rhizome of *Zingiber Officinale*. Phyto chemistry 2004; 65 (8): 1137-1143
13. Gugnani HC, Ezenwanze EC Antibacterial activity of extracts of ginger. J Commun Dis, 17:233; 1985
14. Gupta MB, Palit TK, Bhargava KP, Pharmacological study of isolate the active constituents of *C. rotundus* responsible for anti- inflammatory and analgesic action. Indian J Med Res 1971; 59:76-82.
15. Shinde U.A et al, Preliminary studies on the anti-inflammatory and analgesic activity of *C.deodara* wood oil. J. Ethnopharmacol. 1999; 65: 21-27.
16. Fulzele SV, Sattkrwar PM. Joshi SB, Dorle AK, Studies on anti- inflammatory activity of poly herbal formulation Jatyadi Ghrita. Indian Drugs 2002; 39: 42-44.
17. Priya joy, Patric RD, Anti-bacterial activity studies of *jasminum grandiflorum* and *J. officinale*. Ethnobotanical leaflets 2008; 12: 481-483.
18. Nagesh K, Mohan B Ramesh B, Evaluation of analgesic activity of *J.ausiculatum* on Albino rats, Balaji college of pharmacy, Anantpur Andra Pradesh, India

Cite this article as:

Kanaujia Sakshi, Kumar Manoj. Role of topical application of shringveradi eye drops in netrabhisyanda with special reference to allergic conjunctivitis. J Biol Sci Opin 2015;3(4):170-175
<http://dx.doi.org/10.7897/2321-6328.03437>

Source of support: Nil; Conflict of interest: None Declared

Disclaimer: JBSO is solely owned by Moksha Publishing House - A non-profit publishing house, dedicated to publish quality research, while every effort has been taken to verify the accuracy of the contents published in our Journal. JBSO cannot accept any responsibility or liability for the site content and articles published. The views expressed in articles by our contributing authors are not necessarily those of JBSO editor or editorial board members.